Biosynthesis Technology Could Transform Cannabinoid Production

The upward trajectory of the cannabis industry has garnered comparisons to the Internet boom of the early 2000s, as North American sales are on pace to record a compound annual growth rate of 25 percent through 2021, according to Arcview Market Research (1).

An Overview of International Markets for Canadian Cannabis Companies

As more countries begin to allow some form legalization, opportunities arise for Canadian companies to expand their business. It’s hard to ignore the fact that the boom of Canadian stocks as the country prepares for legal recreational cannabis use has been felt on a global scale.

Alzheimer’s Disease: Cannabis Formulation Shows Promise

Currently, India Globalization Capital (IGC) is the only publicly traded pharmaceutical cannabis stock that addresses Alzheimer’s disease, which positions the company with a first-mover advantage in phytocannabinoid-based combination therapy.

Pot is the new alcohol

Pot is what alcohol used to be. It’s an industry ready to take off, but one that’s still finding its way , and one whose progress is not exactly encouraged by the federal government. It’s a little bit like Prohibition 2.0. 

CanniMed Therapeutics Inc. Reports Financial Results for Q3 2017

CanniMed Therapeutics Inc. (TSX:CMED)today released its financial results for the three and nine months ended July 31, 2017. Highlights Sales of $4.8 million in the quarter were 80 per cent higher than in the comparable period of the prior year and were 29 per cent higher than the second quarter of 2017.